Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models

Emilie Indersie, Sophie Branchereau, Brice Fresneau, Christophe Chardot, Didier Surdez, Alexandra Saint-Charles, Maria Eugénia Marques da Costa, Ángel M. Carcaboso, Katia Scotlandi, Massimo Moro, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Louis Chesler, Chris Jones, Beat Schäfer, Marco Wachtel, Johannes Gojo, Walter Berger, Christina Guttke, Maureen Hattersley, Frédéric Colland, Ashley Strougo, Dennis Gürgen, Jens Hoffmann, Julia Schueler, Pablo M. Aviles, María José Guillén, Aniello Federico, Apurva Gopisetty, Justyna Anna Wierzbinska, Andreas Schlicker, Sara Colombetti, Olaf Heidenreich, Fatima Iradier, Nicole Huebener, Natalie Jäger, Jan Koster, Marcel Kool, Gudrun Schleiermacher, Jan J. Molenaar, Birgit Geoerger, David J. Shields, Hubert N. Caron, Louis F. Stancato, Stefan M. Pfister, Gilles Vassal, Eva-Maria Rief, Olivier Déas

Cancer Res (2024) 84 (6_Supplement): 5469.

https://doi.org/10.1158/1538-7445.AM2024-5469

Published: 22 March 2024

View article titled, Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models

Journal Articles

The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture

Joana Graca Marques, Blaz Pavlovic, Quy A. Ngo, Gloria Pedot, Michaela Roemmele, Larissa Volken, Samanta Kisele, Romain Perbet, Marco Wachtel, Beat W. Schäfer

Cancer Res (2024) 84 (2): 241–257.

https://doi.org/10.1158/0008-5472.CAN-22-3950

Published: 16 January 2024

View article titled, The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture

Includes: Supplementary data

Journal Articles

Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Aniello Federico, Apurva Gopisetty, Didier Surdez, Yasmine Iddir, Alexandra Saint-Charles, Justyna Wierzbinska, Andreas Schlicker, Richard Volckmann, Danny Zwijnenburg, Sara Colombetti, Olaf Heidenreich, Fatima Iradier, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Christina Guttke, Maureen M. Hattersley, Frédéric Colland, Ashley Strougo, María José Guillén, Louis Chesler, Chris Jones, Maria Eugénia Marques da Costa, Katia Scotlandi, Massimo Moro, Beat Schäfer, Marco Wachtel, Johannes Gojo, Walter Berger, Ángel Montero Carcaboso, Dennis Gürgen, Jens Hoffmann, Emilie Indersie, Stefano Cairo, Julia Schueler, Nicole Huebener, Johannes H. Schulte, Jan J. Molenaar, Birgit Geoerger, David J. Shields, Hubert N. Caron, Gilles Vassal, Lou F. Stancato, Lou F. Stancato, Stefan M. Pfister, Natalie Jäger, Jan Koster, Marcel Kool, Gudrun Schleiermacher

Cancer Res (2023) 83 (7_Supplement): 3571.

https://doi.org/10.1158/1538-7445.AM2023-3571

Published: 04 April 2023

View article titled, Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Journal Articles

Abstract 1667: Elimusertib shows stronger antitumor activity than standard of care chemotherapy in pediatric solid tumor models

Cancer Res (2023) 83 (7_Supplement): 1667.

https://doi.org/10.1158/1538-7445.AM2023-1667

Published: 04 April 2023

View article titled, Abstract 1667: Elimusertib shows stronger antitumor activity than standard of care chemotherapy in pediatric solid tumor models

Journal Articles

Abstract 668: A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo

Cancer Res (2022) 82 (12_Supplement): 668.

https://doi.org/10.1158/1538-7445.AM2022-668

Published: 15 June 2022

View article titled, Abstract 668: A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo

Journal Articles

Abstract 3962: Mechanisms of tumor recurrence and drug resistance in rhabdomyosarcoma

Devmini C. Moonamale, Marco Wachtel, Beat W. Schäfer

Cancer Res (2022) 82 (12_Supplement): 3962.

https://doi.org/10.1158/1538-7445.AM2022-3962

Published: 15 June 2022

View article titled, Abstract 3962: Mechanisms of tumor recurrence and drug resistance in rhabdomyosarcoma

Journal Articles

Abstract 1679: Single-cell profiling reveals a conserved myogenic hierarchy in pediatric rhabdomyosarcomas amenable to differentiation therapy

Sara G. Danielli, Ermelinda Porpiglia, Andrea J. De Micheli, Ingrid Bechtold, Joana G. Marques, Stephanie Kasper, Helen M. Blau, Marco Wachtel, Beat W. Schäfer

Cancer Res (2022) 82 (12_Supplement): 1679.

https://doi.org/10.1158/1538-7445.AM2022-1679

Published: 15 June 2022

View article titled, Abstract 1679: Single-cell profiling reveals a conserved myogenic hierarchy in pediatric rhabdomyosarcomas amenable to differentiation therapy

Journal Articles

Abstract 3122: Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma

Carla Regina, Geoffroy Andriuex, Sina Angenendt, Michaela Schneider, Manching Ku, Marie Follo, Marco Wachtel, Eugene Ke, Ken Kikuchi, Anton G. Henssen, Beat W. Schäfer, Melanie Boerries, Amy J. Wagers, Charles Keller, Simone Hettmer

Cancer Res (2021) 81 (13_Supplement): 3122.

https://doi.org/10.1158/1538-7445.AM2021-3122

Published: 01 July 2021

View article titled, Abstract 3122: Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma

Journal Articles

Abstract PO-009: Disrupting chromatin architecture: The NuRD subunit and ATPase CHD4 as a new therapeutic target in pediatric sarcoma

Joana G. Marques, Berkley Gryder, Blaz Pavlovic, Yeonjoo Chung, Quy Ngo, Marco Wachtel, Javed Khan, Beat Schäfer

Cancer Res (2020) 80 (23_Supplement): PO-009.

https://doi.org/10.1158/1538-7445.EPIMETAB20-PO-009

Published: 02 December 2020

View article titled, Abstract PO-009: Disrupting chromatin architecture: The NuRD subunit and ATPase CHD4 as a new therapeutic target in pediatric sarcoma

Journal Articles

Abstract 3900: The BRG1 ATPase helps to maintain the de-differentiation phenotype in alveolar rhabdomyosarcoma

Dominik Laubscher, Benjamin Z. Stanton, Berkley Gryder, Sudipto Das, Thorkell Andresson, Bernd Roschitzki, Witold Wolski, QuyAi Ngo, Joana G. Marques, Marco Wachtel, Christopher Vakoc, Javed Khan, Beat Schäfer

Cancer Res (2020) 80 (16_Supplement): 3900.

https://doi.org/10.1158/1538-7445.AM2020-3900

Published: 15 August 2020

View article titled, Abstract 3900: The BRG1 ATPase helps to maintain the de-differentiation phenotype in alveolar rhabdomyosarcoma

Journal Articles

Abstract B12: PAX3 translocations co-opt super enhancers and intrinsically disordered fusion partners in rhabdomyosarcoma

Berkley E. Gryder, Marco Wachtel, Winston Ewert, Kenneth Chang, Osama El Demerdash, Young Song, Beat W Schäfer, Christopher R. Vakoc, Javed Khan

Cancer Res (2020) 80 (14_Supplement): B12.

https://doi.org/10.1158/1538-7445.PEDCA19-B12

Published: 15 July 2020

View article titled, Abstract B12: PAX3 translocations co-opt super enhancers and intrinsically disordered fusion partners in rhabdomyosarcoma

Journal Articles

Abstract B56: A CRISPR/Cas9 domain screen identifies a small motif in the PAX3-FOXO1 transactivation domain relevant for tumor maintenance in alveolar rhabdomyosarcoma

Marco Wachtel, Katharina Benischke, Beat W. Schäfer

Cancer Res (2020) 80 (14_Supplement): B56.

https://doi.org/10.1158/1538-7445.PEDCA19-B56

Published: 15 July 2020

View article titled, Abstract B56: A CRISPR/Cas9 domain screen identifies a small motif in the PAX3-FOXO1 transactivation domain relevant for tumor maintenance in alveolar rhabdomyosarcoma

Journal Articles

Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death

Johannes Ommer, Joanna L. Selfe, Marco Wachtel, Eleanor M. O'Brien, Dominik Laubscher, Michaela Roemmele, Stephanie Kasper, Olivier Delattre, Didier Surdez, Gemma Petts, Anna Kelsey, Janet Shipley, Beat W. Schäfer

Cancer Res (2020) 80 (4): 832–842.

https://doi.org/10.1158/0008-5472.CAN-19-1479

Published: 14 February 2020

View article titled, Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death

Includes: Supplementary data

Journal Articles

Abstract 3116: Targeting fibroblast growth factor receptors in rhabdomyosarcoma

Nagjie Alijaj, Sandrine Moutel, Maxim Gray, Maurizio Roveri, Gabriele Manzella, Marco Wachtel, Franck Perez, Beat Schäfer, Michele Bernasconi

Cancer Res (2019) 79 (13_Supplement): 3116.

https://doi.org/10.1158/1538-7445.AM2019-3116

Published: 01 July 2019

View article titled, Abstract 3116: Targeting fibroblast growth factor receptors in rhabdomyosarcoma

Journal Articles

Abstract B01: Development of an in vitro drug-profiling platform for functional guidance of treatment decisions and identification of vulnerabilities in chemoresistant relapsed rhabdomyosarcoma tumors

Beat W. Schaefer, Gabriele Manzella, Michaela Roemmele, Luduo Zhang, Joëlle Tchinda, Felix Niggli, Marco Wachtel

Cancer Res (2018) 78 (19_Supplement): B01.

https://doi.org/10.1158/1538-7445.PEDCA17-B01

Published: 01 October 2018

View article titled, Abstract B01: Development of an in vitro drug-profiling platform for functional guidance of treatment decisions and identification of vulnerabilities in chemoresistant relapsed rhabdomyosarcoma tumors

Journal Articles

Abstract 3194: Development of an in vitro drug profiling platform with primary Rhabdomyosarcoma cells for tailoring patient-specific treatments

Marco Wachtel, Gabriele Manzella, Michaela Römmele, Luduo Zhang, Joelle Tchinda, Felix Niggli, Beat Schäfer

Cancer Res (2018) 78 (13_Supplement): 3194.

https://doi.org/10.1158/1538-7445.AM2018-3194

Published: 01 July 2018

View article titled, Abstract 3194: Development of an <em>in vitro</em> drug profiling platform with primary Rhabdomyosarcoma cells for tailoring patient-specific treatments

Journal Articles

Abstract 4630: Characterizing oncogene addiction in alveolar rhabdomyosarcoma reveals novel strategies for combination therapy

Johannes Ommer, Marco Wachtel, Beat W. Schaefer

Cancer Res (2018) 78 (13_Supplement): 4630.

https://doi.org/10.1158/1538-7445.AM2018-4630

Published: 01 July 2018

View article titled, Abstract 4630: Characterizing oncogene addiction in alveolar rhabdomyosarcoma reveals novel strategies for combination therapy

Journal Articles

Abstract 1393: Chromatin remodelers as potential new targets for therapy of pediatric sarcoma

Joana G. Marques, Berkley Gryder, Marco Wachtel, Javed Khan, Beat Schaefer

Cancer Res (2017) 77 (13_Supplement): 1393.

https://doi.org/10.1158/1538-7445.AM2017-1393

Published: 01 July 2017

View article titled, Abstract 1393: Chromatin remodelers as potential new targets for therapy of pediatric sarcoma

Journal Articles

Abstract 700: Characterization of the mode of action of Fenretinide treatment in alveolar rhabdomyosarcoma cells

Eva Brack, Marco Wachtel, Beat W. Schaefer

Cancer Res (2017) 77 (13_Supplement): 700.

https://doi.org/10.1158/1538-7445.AM2017-700

Published: 01 July 2017

View article titled, Abstract 700: Characterization of the mode of action of Fenretinide treatment in alveolar rhabdomyosarcoma cells

Journal Articles

Abstract 4992: Miswired super enhancer logic driving childhood sarcoma

Berkley E. Gryder, Marco Wachtel, Hsien-Chao Chou, Young Song, Joana Marques, Beat Schaefer, Javed Khan

Cancer Res (2017) 77 (13_Supplement): 4992.

https://doi.org/10.1158/1538-7445.AM2017-4992

Published: 01 July 2017

View article titled, Abstract 4992: Miswired super enhancer logic driving childhood sarcoma

NARROW

Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models

The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture

Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Abstract 1667: Elimusertib shows stronger antitumor activity than standard of care chemotherapy in pediatric solid tumor models

Abstract 668: A MYOD-SKP2 axis boosts oncogenic properties of fusion negative rhabdomyosarcoma and is counteracted by neddylation inhibition in vitro and in vivo

Abstract 3962: Mechanisms of tumor recurrence and drug resistance in rhabdomyosarcoma

Abstract 1679: Single-cell profiling reveals a conserved myogenic hierarchy in pediatric rhabdomyosarcomas amenable to differentiation therapy

Abstract 3122: Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma

Abstract PO-009: Disrupting chromatin architecture: The NuRD subunit and ATPase CHD4 as a new therapeutic target in pediatric sarcoma

Abstract 3900: The BRG1 ATPase helps to maintain the de-differentiation phenotype in alveolar rhabdomyosarcoma

Abstract B12: PAX3 translocations co-opt super enhancers and intrinsically disordered fusion partners in rhabdomyosarcoma

Abstract B56: A CRISPR/Cas9 domain screen identifies a small motif in the PAX3-FOXO1 transactivation domain relevant for tumor maintenance in alveolar rhabdomyosarcoma

Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death

Abstract 3116: Targeting fibroblast growth factor receptors in rhabdomyosarcoma

Abstract B01: Development of an in vitro drug-profiling platform for functional guidance of treatment decisions and identification of vulnerabilities in chemoresistant relapsed rhabdomyosarcoma tumors

Abstract 3194: Development of an in vitro drug profiling platform with primary Rhabdomyosarcoma cells for tailoring patient-specific treatments

Abstract 4630: Characterizing oncogene addiction in alveolar rhabdomyosarcoma reveals novel strategies for combination therapy

Abstract 1393: Chromatin remodelers as potential new targets for therapy of pediatric sarcoma

Abstract 700: Characterization of the mode of action of Fenretinide treatment in alveolar rhabdomyosarcoma cells

Abstract 4992: Miswired super enhancer logic driving childhood sarcoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only